News on diagnostics for respiratory pathogens, including influenza, coronavirus, and more.
The drug developer said that the biomarker panel will form the basis of a planned point-of-care test for acute respiratory distress syndrome.
The anticipated shortage for clinics comes at a time when more clinicians are already switching to lab-based IGRA testing, diagnostic industry executives said.
Stakeholders discussed last year's decision by Palmetto to deny coverage for large respiratory panels and discussed the way forward for test developers and labs.
Flu test sales were the second-highest for a quarter in the firm's history but were still $17.4 million lower than the year-ago quarter due to a much less intense flu season.
The company envisions creating a "vocometer … to provide disease screening and management solutions based on acoustic analysis of seconds of voice."
